RSS Mainz Biomed, Quest Diagnostics To Commercialize NextGen Colorectal Cancer Screening Test; Stock Up

Currently reading:
 RSS Mainz Biomed, Quest Diagnostics To Commercialize NextGen Colorectal Cancer Screening Test; Stock Up

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
6,599
Likes
1,919
Credits
32,844©
Cash
0$
Mainz Biomed N.V. (MYNZ) announced a strategic partnership with Quest Diagnostics Inc. (DGX) to introduce their NextGen-ColoAlert, an advanced colorectal cancer screening test, to the market. This stool-based diagnostic tool leverages polymerase chain reaction (PCR) technology to detect DNA markers specific to colorectal cancer, facilitating early-stage cancer detection.

Under the terms of the agreement, Quest will deliver clinical trial laboratory services to support Mainz Biomed's ReconAAsense study. Moreover, Mainz Biomed grants Quest an option to obtain semi-exclusive rights to offer testing services using the ColoAlert test kit for a period of 18 months, contingent upon FDA approval, as stated by the company.

On the Nasdaq, Mainz's stock is currently up by 26.42 percent, trading at $4.78.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips
Top Bottom